Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment | Zendy

Richard A. Preston | Zendy; Grigor Mamikonyan | Zendy; Mushtaque Mastim | Zendy; Dyal C. Garg | Zendy; Christopher J. Kemper | Zendy; Allan Xu | Zendy; Ravindra Yeole | Zendy; Rajesh Chavan | Zendy; H. David Friedland | Zendy; Ashima Bhatia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment

Author(s) -

Richard A. Preston,

Grigor Mamikonyan,

Mushtaque Mastim,

Dyal C. Garg,

Christopher J. Kemper,

Allan Xu,

Ravindra Yeole,

Rajesh Chavan,

H. David Friedland,

Ashima Bhatia

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00873-19

Subject(s) - cefepime , tazobactam , pharmacokinetics , medicine , piperacillin/tazobactam , intensive care medicine , pharmacology , piperacillin , antibiotics , imipenem , biology , microbiology and biotechnology , genetics , antibiotic resistance , pseudomonas aeruginosa , bacteria

WCK 4282 is a combination product of cefepime (FEP) and tazobactam (TAZ) in a 1:1 ratio currently under development for the treatment of multidrug-resistant Gram-negative bacterial infections. We investigated the effect of renal impairment on the pharmacokinetics (PK) and safety of WCK 4282 in 48 subjects with various degrees of renal function. Subjects were categorized on the basis of their Cockcroft-Gault equation-estimated creatinine clearance (CLCR ).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research